Based on the daily chart (1D), the technical indicators are flashing a strongly bullish signal, aligning perfectly with the fundamental story regarding ASP hikes and the Middle East disruptions.

Here is the interpretation of the indicators:

1. Price & Moving Averages (Bullish Breakout)

· Action: The stock is trading at RM 1.230, up +4.24% today. It has broken out of a tight consolidation zone.
· Signal: It has decisively moved above both the MA50 (Green line at 1.045) and is well positioned above the MA200 (Blue line). This is a classic "Golden Cross" confirmation in progress. The price staying above these major moving averages indicates the long-term trend has shifted from bearish/cautious to bullish/confirming recovery.

2. Volume (Massive Confirmation)

· Signal: There is a massive surge in volume (42.804M). This is much higher than the average volume over the previous weeks.
· Meaning: The breakout at 1.230 is legitimate. It is not a "fake-out" move. Institutional players or big funds are aggressively buying in the lead-up to the anticipated earnings boom.

3. RSI (Strong Momentum Without Overheating)

· Level: The RSI 14 is at 63.44.
· Meaning: The stock is gaining very strong momentum. An RSI reading between 50 and 70 indicates a healthy uptrend. It hasn't crossed into overbought territory (above 70) yet, meaning there is still potential for the price to run to RM 1.30 or RM 1.40 before needing a major pullback.

4. MACD (Turning Positive)

· Status: The MACD lines are sitting at 0.030 and 0.029, with the histogram barely visible.
· Meaning: Earlier, the MACD was showing a bearish/signal line crossing down. However, with today's surge, the two lines are converging for a fresh bullish crossover. If the price closes strong at 1.230, expect the MACD to turn fully green in the next session. This confirms that the momentum is shifting back in favor of the bulls.

💡 Overall Technical Conclusion

This chart confirms the "Revaluation Story" is beginning.
The market is clearly anticipating the August QR where the US$26-28 thousand ASP numbers will appear in the P&L statement.

Caution: The trend is your friend, but chasing the exact top of a large candle is risky.

Happy trading everyone

Sharing as I have skin in the game……

KUALA LUMPUR (May 8): New Paradigm Research in a note on Friday said it expects glove makers’ earnings to double in one to two quarters on glove makers' unique opportunity to raise prices above and beyond direct cost impacts.

This is supported by industry-wide price adjustments, US tariffs limiting Chinese imports, and delayed increases in gas costs for producers.

The research house is more optimistic than the market, forecasting 60%–80% higher earnings for glove makers because it believes they can raise selling prices despite higher nitrile costs. However, it also notes that prices and costs remain volatile and assumes a 5% drop in demand. While the market is cautious due to recent data showing glove prices fell in March. However, nitrile material costs have clearly increased.

New Paradigm believes most market forecasts focus on sales volume instead of price increases and have not fully included profit margin improvements. It expects that as earnings improve over the next two quarters, glove company valuations will likely rise as well.

Since the closure of the Strait of Hormuz, the nitrile prices have surged as the closure disrupted naphtha supply flows into Asia. Nitrile, which makes up roughly 40% of glove production costs, is derived from naphtha.

Malaysian glove makers source around 65% of their nitrile requirements from South Korea, which itself relies heavily on Middle Eastern naphtha imports.

New Paradigm estimates nitrile prices have risen about 60% on average since the conflict began. Still, the research house noted that the entire global glove industry, including Chinese competitors, is facing similar cost pressures, too. This allows Malaysian manufacturers to pass higher costs to customers more effectively, it added.

“Demand for medical disposable gloves is non-discretionary in nature,” New Paradigm said, adding that substitution to latex gloves is not viable because of allergy risks and the natural rubber gloves also tend to be less durable and not suitable for all applications.

The sector’s pricing power is also being strengthened by the US’ Section 301 tariffs on Chinese glove imports, which have effectively priced low-margin Chinese gloves out of the US market. Malaysian manufacturers now account for more than 60% of US glove imports by volume, while China’s market share has fallen to below 10% from over 30% previously, the house added.

“The bias for conservatism and the “wait and see” approach present an opportunity — once the earnings delivery trickles in, the upgrades to expectations could spur a more substantive rerating for valuations as well,” New Paradigm added.

It said that since the Covid-19 boom years, analysts have not significantly raised their earnings forecasts in the middle of the year.

The firm estimates that Top Glove Corp Bhd (KL:TOPGLOV) could see net profit almost double sequentially, while Hartalega Holdings Bhd (KL:HARTA) could record around 60% sequential earnings growth.

Shares of major Malaysian glove manufacturers rebounded on Friday morning, with Top Glove, Hartalega and Kossan rising between 6% and 8%. The gains coincided with the market reaction to reports of a hantavirus outbreak in South America.

CSG International Research analyst William Wo said it maintains a cautious view on the sector after noting that the World Health Organization had described the Andes strain as having a fatality rate of about 35%, although human-to-human transmission remains rare. Symptoms include fever, chills and breathing difficulties that may only appear several weeks after infection.

HARTA is delivering a textbook technical breakout, where the charts are telling:

1. The Massive Breakout

· The Action: The stock rocketed +8.13% to RM 1.33. It has violently broken above the consolidation zone (the previous resistance ceiling around 1.20 - 1.25).
· The Meaning: This breakout confirms the stock has left its sideways/digestion phase. Market sentiment has flipped decisively bullish. The re-rating based on the new ASP (~$26-28/k) is accelerating.

2. Technicals are Flashing "Buy" Signals

· Volume (Heavy): The volume bars are massive. This indicates institutional money is piling in, not just retail chasing headlines. This is a high-conviction breakout.
· Golden Cross (MA 50 & MA 200): The MA 50 (1.054) is clearly set to cross above the MA 200 (1.103). This is the single strongest long-term bullish signal in a chart. It indicates the 50-day trend is now stronger than the 200-day trend.
· MACD (Bullish Cross Confirmed): The MACD line has crossed above the signal line (0.041 vs 0.032), and the histogram has flipped to green (positive 0.009). This confirms the momentum is now fully on the side of the buyers.

3. The Only Watch-Out: RSI (Overbought)

· RSI 14 is at 71.05. This is technically overbought (anything above 70 is considered overextended).
· What this means: It does not mean the rally is over. In a strong trend (like this one), stocks can stay overbought for a while. However, it does mean you should not chase the stock right at the very top of a huge green candle (1.33). The price is very sensitive to a quick "profit-taking" pullback.

The stock is at 1.330, sitting roughly mid-range between the recent breakout (1.25) and the recent high watermark (1.375). After a massive 8%+ run-up yesterday, the stock is consolidating sideways. This is a normal and very healthy behavior. It allows the moving averages (MA 50) to "catch up" to the price.

Here is a clear summary and conclusion of WHO's announcement from 11 hours ago:

· The Situation: WHO has officially declared a Public Health Emergency of International Concern (PHEIC) for the Ebola outbreak in the Democratic Republic of the Congo (DRC) and Uganda.
· The Virus: It is caused by the Bundibugyo virus, not the more common Zaire Ebola strain.
· Crucial Difference: Unlike the Zaire strain, there are currently NO approved vaccines or specific therapeutics for the Bundibugyo virus. This is a major reason the event is considered "extraordinary."
· The Numbers (as of May 16, 2026):
· DRC: 8 confirmed cases, 246 suspected cases, and 80 suspected deaths in Ituri Province.
· Uganda: 2 confirmed cases (including 1 death) in Kampala, linked to travel from DRC.
· The Risk: WHO is concerned the true scope of the outbreak is much larger due to high positivity rates, community deaths, insecurity in the region, and the detection of cases in major cities like Kampala and Kinshasa.
· WHO Advice:
· DRC & Uganda: Must immediately activate emergency response, enhance surveillance, and ensure safe burials.
· Neighboring Countries: Must urgently enhance preparedness and screening at borders.
· The World: No country should close its borders or restrict trade/travel. Travelers to the region should be given accurate risk information.

The International Health Regulations Emergency Committee on #Ebola caused by Bundibugyo virus in #DRC and #Uganda will meet today, 19 May 2026 from 17h30 CEST (GMT+2) bit.ly/4fvo7nz

@DrTedros determined the event constitutes a public health emergency of international concern on 17 May 2026

The technical outlook for Hartalega (HARTA) is solidly bullish, confirming a definitive trend reversal.

Here is the breakdown of the key signals:

1. The Golden Cross (The Most Important Signal)

The MA 50 (Green line at 1.128) is crossing above the MA 200 (Blue line at 1.098). This is a classic Golden Cross, which is one of the strongest long-term bullish signals in technical analysis. It indicates that the 50-day trend has officially overtaken the 200-day trend, signaling a structural shift from bearish to bullish.

2. Price Action & Uptrend Confirmation

The stock recently pulled back to around 1.25-1.26 (after hitting a high of 1.375) and has bounced off that level successfully. Today's move to 1.320 (+1.54%) shows buyers are stepping back in aggressively to defend the new support zone. The price is making higher highs and higher lows.

3. RSI (Momentum)

The RSI is sitting at 63.74. This is a very healthy level. It confirms strong buying pressure, but it is not yet overbought (above 70). This means there is still plenty of room for the stock to rise before a major cooling-off period is needed.

4. MACD (Momentum)

The MACD histogram has flipped back from red to a very small positive green (0.003), and the fast line is angled upward, converging with the signal line. This suggests the short-term momentum has turned back in favor of the bulls after the brief pause.

🎯 The "Now" Strategy

· Support: The level of 1.25 - 1.28 has now been successfully tested and confirmed as solid support.
· Resistance: The immediate target is to test the recent high of 1.375. If it breaks that, the next major resistance zone (based on historical supply) lies between 1.50 - 1.80.

Conclusion: The chart looks very healthy. It's not a "parabolic" bubble move, but a structured, legitimate recovery trend with solid technical foundations. The "Sell in May" seasonality seems to have been fully absorbed, and the stock is gearing up for a potential test of higher levels.

How true is this allegation?!

BREAKING: Laura Loomer claims a massive Ebola cover-up is taking place inside the United States.

➡️ @RealTimeDailyNews

Q: How does the #Ebola virus spread from one person to another?
A: Ebola spreads through direct contact with the blood, body fluids, or tissues of an infected person, including someone who has died from the disease. It can also spread through contaminated objects such as bedding, clothing or medical equipment. Health workers and caregivers are at higher risk if infection prevention measures are not strictly followed.

Q: What are the common signs and symptoms of #Ebola infection?
A: Common symptoms include sudden fever, weakness, headache, muscle pain and sore throat. As the disease progresses, patients may develop vomiting, diarrhea, rash, stomach pain and, in some cases, bleeding. Symptoms can appear between 2 and 21 days after exposure to the virus.

Q: Which groups of people are most at risk of getting #Ebola?
A: People most at risk include hunters, family members caring for infected relatives, health workers without adequate protective equipment, laboratory personnel handling samples, and individuals involved in unsafe burial practices. Communities with frequent population movement or limited access to healthcare may also face increased risk during outbreaks.

Based on Top Glove’s recently released 3QFY2026 results, we now have a very reliable leading indicator for Hartalega’s upcoming August quarterly report (which covers April to June 2026).

When we compare the two, Top Glove reported revenue of RM1.095 billion and a net profit (PATAMI) of RM81 million for the quarter. While Hartalega’s previous quarter only generated RM515 million in revenue and RM40 million in net profit, the comparison isn’t as straightforward as it seems. Top Glove’s numbers were inflated by a large impairment write-off of nearly RM30 million, and despite having much higher revenue, their earnings per share (EPS) of 1.01 sen was actually lower than Hartalega’s EPS of 1.19 sen. This clearly proves that Hartalega’s highly automated factories are vastly more efficient when it comes to converting sales into actual profit per share.

Looking forward, the most important thing to remember is that Hartalega’s last reported quarter (ending March 2026) did not yet fully reflect the sharp increase in average selling prices (ASPs) to US28 per thousand pieces. Because Top Glove has now confirmed that they successfully passed on rising raw material costs to their customers, we can expect Hartalega to benefit from the exact same pricing tailwind.

For Hartalega’s upcoming August report, I am projecting quarterly revenue to rise modestly to somewhere between RM550 million and RM580 million. Since Hartalega is already running near full utilization, revenue growth will not be massive. However, the real story will be on the bottom line. With their superior cost automation and higher selling prices in full effect, I estimate Hartalega’s net profit could jump to between RM65 million and RM75 million for the quarter. That would push their earnings per share to around 1.90 to 2.20 sen—a dramatic improvement from the previous quarter.

Of course, there is always risk in this sector. The current stock price of around RM1.06 is being dragged down by weak market sentiment following Top Glove’s release, but the fundamentals for Hartalega remain intact. The recovery in glove profitability is real, and Hartalega is positioned to capture that recovery much more efficiently than its peers. If Hartalega delivers an EPS of 2.0 sen or higher in August, the market will likely re-rate the stock sharply higher.

In short, the current weakness appears to be temporary sector-wide panic rather than a reflection of Hartalega’s true earnings potential. The August quarterly result is shaping up to be a genuine profit shock, and long-term shareholders could be well rewarded for holding through this volatility.